Journal Mobile Options
Table of Contents
Vol. 203, No. 1, 2001
Issue release date: 2001
Dermatology 2001;203:38–44
(DOI:10.1159/000051701)

Acne Resolution Rates: Results of a Single-Blind, Randomized, Controlled, Parallel Phase III Trial with EE/CMA (Belara®) and EE/LNG (Microgynon®)

Worret I. · Arp W. · Zahradnik H.-P. · Andreas J.-O. · Binder N.
aDepartment of Dermatology, University Hospital Munich, bTreatment Centre for Gynaecology and Obstetrics, Kiel, cDepartment of Gynaecology and Obstetrics, University Hospital Freiburg, and dGrünenthal GmbH, Aachen, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background and Objective: Acne in women can often be successfully treated by the intake of oral contraceptives containing gestagens with anti-androgenic properties. This study aimed to evaluate the efficacy of the monophasic oral contraceptive ethinylestradiol/chlormadinone acetate (EE/CMA; Belara®) for the treatment of mild to moderate papulopustular acne of the face and acne-related disorders in comparison to EE/levonorgestrel (LNG; Microgynon®). Methods: 199 female acne patients were enrolled in a single-blind, randomized, multicentre phase III study and divided into two groups who received either EE/CMA or EE/LNG. The primary end point was fulfilled if the number of papules/pustules per half of the face present on admission had decreased by at least 50% in the 12th medication cycle. Results: 59.4% of the women under EE/CMA and 45.9% under EE/LNG were responders. The relative frequency of women with complete resolution was 16.5% under EE/CMA and 4.3% under EE/LNG at cycle 12.Conclusion: EE/CMAis an efficient treatment for women with mild and moderate papulopustular acne of the face and related disorders, reflecting the well-known anti-androgenic properties of the progestogen CMA.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kaiser E: Action of a new hormonal contraceptive (Neo-Eunomin®) on androgenisation of the skin in women. Geburtsh Frauenheilkd 1984;44:651–655.
  2. Carlborg L: Cyproterone acetate versus levonorgestrel combined with ethinylestradiol in the treatment of acne. Acta Obstet Gynecol Scand 1986;134:29–32.
  3. McKenna TJ: The use of anti-androgens in the treatment of hirsutism. Clin Endocrinol 1991;35:1–3.
  4. Dieben T, Vromans L, Theeuwes C, Bennink HJT: The effects of CRT-24, a biphasic oral contraceptive combination, compared to Diane-35 in women with acne. Contraception 1994;50:373–382.

    External Resources

  5. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL: Norgestimate and ethinylestradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615–622.
  6. Ebling FJ: Hormonal control of sebaceous glands in experimental animals; in Montagna W, Ellis RA, Silver AF (eds): Advances in the Biology of Skin: The Sebaceous Gland. Oxford, Pergamon Press, 1963, vol 4, pp 200–219.
  7. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ: Effectiveness of norgestimate and ethinylestradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746–754.
  8. Breckwoldt M, Wieacker P: Hirsutismus; in Bettendorf G, Breckwoldt M (eds): Reproduktionsmedizin. Stuttgart, Fischer, 1989, pp 483–487.
  9. Breckwoldt M, Zahradnik HP, Wieacker P: Hirsutism; in Orfanos CE, Happle R (eds): Hair and Hair Diseases. Berlin, Springer, 1990, pp 777–789.
  10. Cook H, Centner RL, Michael SE: An acne grading method using photographic standards. Arch Dermatol 1979;115:571–575.
  11. Plewig G: Klassifikation und Ätiopathogenese der Akne; in Braun-Falco O, Marghescu S (eds): Fortschr Prakt Dermatol Venerol 1976;8:1279–1288.
  12. Sansone G, Reisner RM: Differential rates of conversion of testosterone to dihydrotestosterone in acne and in normal human skin – Possible pathogenetic factors in acne. J Invest Dermatol 1971;56:366–372.
  13. Fugère P, Robin KL, Lussier-Cacan S, Davignon J, Farquhar D: Cyproterone acetate/ethinylestradiol in the treatment of acne: A comparative dose-response study of the estrogen component. Contraception 1990;42:225–234.
  14. Dubé JY, Ngo-Thi NH, Tremblay RR: In vivo effects on steroid hormones on the testosterone 5-α-reductase in rat skin. Endocrinology 1975;97:211–214.

    External Resources

  15. Frost P, Gomez EC: Inhibitors of sex hormones: Development of experimental models; in Montagna W, van Scott EJ, Stoughton RB (eds): Advantages in Biology of Skin. Pharmacology and Skin. New York, Meredith Corp, 1972, vol XII, pp 403–442.
  16. Dericks-Tan JSE, Gudacker V, Taubert HD: Influence of oral contraceptives on integrated secretion of gonadotropins. Contraception 1992;46:369–377.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50